Small Molecule Inhibition of GSK-3 Specifically Inhibits the Transcription of Inhibitory Co-receptor LAG-3 for Enhanced Anti-tumor Immunity
Christopher E. Rudd(Hôpital Maisonneuve-Rosemont), Alison Taylor(University of Leeds)
Cited by 74
Related Papers
How the Discovery of the CD4/CD8-p56lck Complexes Changed Immunology and Immunotherapy
|Frontiers in Cell and Developmental Biology|2021|54
TcR and TcR-CD28 Engagement of Protein Kinase B (PKB/AKT) and Glycogen Synthase Kinase-3 (GSK-3) Operates Independently of Guanine Nucleotide Exchange Factor VAV-1
|Journal of Biological Chemistry|2006|48
Elraglusib (9-ING-41), a selective small-molecule inhibitor of glycogen synthase kinase-3 beta, reduces expression of immune checkpoint molecules PD-1, TIGIT and LAG-3 and enhances CD8+ T cell cytolytic killing of melanoma cells
|Journal of Hematology & Oncology|2022|46
SKAP1 Protein PH Domain Determines RapL Membrane Localization and Rap1 Protein Complex Formation for T Cell Receptor (TCR) Activation of LFA-1
|Journal of Biological Chemistry|2011|38